Hepatocellular carcinoma
Conditions
Interventions
Sponsors
Kinki University School of Medicine Department of Surgery
Human Genome Center, Institute of Medical Science, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.It is diagnosed as the hepatocellular carcinoma by the case history and the diagnostic imaging. There is no adjustment of The operation, the radio wave cauterizing treatment, the transcatheter arterial embolization therapy,chemotherapy,radiotherapy,and the molecular-targeted therapy . 2.Performance status 0or1 3.The age when registering is from 20 or more to 80 years old or less. 4.There must be change to a morbid lesion that can be the measurement by RECIST. 5.Four weeks or more must pass from the prior treatment. 6.The vital prognosis should be able to be expected for three months or more. 7.WBC >= 1,500 and <=15,000,Platelet >=50,000/mm3 ,Child-PughAorB,Three times or less of keeping kidney function creatinine standard value. 8.Possess HLA-A*2402. 9.Understand the content of treatment, and obtain the person in question's agreement with the document.
Exclusion criteria
Exclusion criteria: 1.The patient who has gullet or gastric varix, with the past of hemorrhage.The one of red color sign (RC2 or more) positivity regardless of the varicosity or F factor of F2 or more. (gullet and stomach varicosity endoscope guideline) 2.The one with pregnant woman, breast-feeding woman, and likelihood of pregnancy and the one in which pregnancy is hoped 3.It has a difficult briskness infectious disease to control. 4.The one with necessity for administering the following medicines while examining it. Whole body administration of adrenal steroid medicine and immunosuppressive agent's whole body administration (As for NSAIDS use is admitted). 5.After the liver transplant 6.It was admitted that the doctor was not suitable. 7.The one to hope for medical treatment to present disease such as Chemotherapy and Molecular-targeted therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of safety and specific immune response | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival(PFS) Overall survival(OS) | — |
Countries
Japan
Contacts
Public ContactYasuyuki Nakata
Kinki University School of Medicine Department of Surgery
Outcome results
None listed